Epizyme, Inc. is an integrated biopharmaceutical company committed to rewriting treatment for cancer and other diseases through transformative epigenetic medicines. Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them.